|
- Comparative effectiveness of pembrolizumab vs. nivolumab in patients . . .
Survival analysis of patients receiving combination therapy as second- or further-line therapy showed that nivolumab had better efficacy than pembrolizumab However, the multivariate analysis revealed no significant difference in PFS between patients treated with pembrolizumab and those treated with nivolumab regardless of the subgroup
- Pembrolizumab vs. nivolumab: How do they compare? - Drugs. com
Pembrolizumab (brand name: Keytruda) and nivolumab (brand name: Opdivo) are both prescription medications used to treat many different types of cancers, including solid tumors and blood cancers They may be used alone or in combination with other medicines for cancers that are more advanced, have spread in the body, or are no longer responding to previous treatments Both pembrolizumab and
- Nivolumab and pembrolizumab: Monoclonal antibodies against programmed . . .
Nivolumab and pembrolizumab work by interfering with the interaction between PD-1 and programmed death ligand-1 (PD-L1), whose unimpeded interaction downregulates T cells allowing cancer cells to evade immune surveillance
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung . . .
Patients in the placebo-combination group in whom disease progression was verified by blinded, independent central radiologic review were eligible to cross over to receive pembrolizumab monotherapy
- Opdivo vs. Keytruda: What’s the difference? - Medical News Today
Opdivo (nivolumab) and Keytruda (pembrolizumab) are brand-name biologic drugs prescribed for several types of cancer They are given by a healthcare professional as an intravenous (IV) infusion
- Real-world comparison of pembrolizumab and nivolumab in advanced . . .
Background Nivolumab and pembrolizumab have not been directly compared in clinical trials, and the aim of this study is to investigate the efficacy and safety of nivolumab versus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) in real-world practice Methods We retrospectively reviewed patients with HCC who received intravenous nivolumab or pembrolizumab alone as second
- Keytruda vs Opdivo: Differences Between Immunotherapy Drugs - GoodRx
The bottom line Keytruda (pembrolizumab) and Opdivo (nivolumab) are immune checkpoint inhibitors (ICIs) that have similar side effects Keytruda is used more often because it has more FDA-approved indications Both medications can be used alone, in combination with chemotherapy, or with tyrosine kinase inhibitors (TKIs)
- Comparison of platinum combination chemotherapy plus pembrolizumab . . .
The safety and efficacy data suggest an unfavourable benefit–risk profile for nivolumab–ipilimumab combined with platinum-based chemotherapy relative to pembrolizumab combined with platinum-based chemotherapy as a first-line treatment for patients with advanced NSCLC, although a definitive conclusion awaits an updated analysis of overall survival
|
|
|